BACKGROUND: Recent studies have shown that circulating branched-chain amino acids (BCAAs) are elevated in obese, insulin-resistant individuals. However, it is not known if supplementation of additional BCAAs will further impair glucose metabolism. OBJECTIVES: The aim of this pilot study was to determine the effects of BCAA supplementation on glucose metabolism in obese, prediabetic individuals. METHODS: This is a randomized crossover study involving 12 obese individuals with prediabetes. Participants were randomly assigned to receive a daily supplement containing either 20 g BCAA or protein low in BCAAs for 4 wk with a 2-wk washout in between. At each visit, an oral-glucose-tolerance test (OGTT) was performed. Collected blood samples were used to measure glucose, insulin, and insulin resistance-associated biomarkers. RESULTS:BCAA supplementation tended to decrease the plasma glucose area under the curve (AUC) measured by the OGTT (AUC percentage change from supplementation baseline, BCAA: -3.3% ± 3%; low-BCAA: 10.0% ± 6%; P = 0.08). However, BCAA supplementation did not affect plasma insulin during OGTT challenge (BCAA: -3.9% ± 8%; low-BCAA: 14.8% ± 10%; P = 0.28). The plasma concentrations of nerve growth factor (BCAA: 4.0 ± 1 pg/mL; low-BCAA: 5.7 ± 1 pg/mL; P = 0.01) and monocyte chemoattractant protein-1 (BCAA: -0.4% ± 9%; low-BCAA: 29.0% ± 18%; P = 0.02) were significantly lowered by BCAA supplementation compared to low-BCAA control. Plasma interleukin 1β was significantly elevated by BCAA supplementation (BCAA: 231.4% ± 187%; low-BCAA: 20.6% ± 33%; P = 0.05). BCAA supplementation did not affect the circulating concentrations of the BCAAs leucine (BCAA: 9.0% ± 12%; low-BCAA: 9.2% ± 11%), valine (BCAA: 9.1% ± 11%; low-BCAA: 12.0% ± 13%), or isoleucine (BCAA: 2.5% ± 11%; low-BCAA: 7.3% ± 11%). CONCLUSIONS: Our data suggest that BCAA supplementation did not impair glucose metabolism in obese, prediabetic subjects. Further studies are needed to confirm the results seen in the present study. This study was registered at clinicaltrials.gov as NCT03715010.
RCT Entities:
BACKGROUND: Recent studies have shown that circulating branched-chain amino acids (BCAAs) are elevated in obese, insulin-resistant individuals. However, it is not known if supplementation of additional BCAAs will further impair glucose metabolism. OBJECTIVES: The aim of this pilot study was to determine the effects of BCAA supplementation on glucose metabolism in obese, prediabetic individuals. METHODS: This is a randomized crossover study involving 12 obese individuals with prediabetes. Participants were randomly assigned to receive a daily supplement containing either 20 g BCAA or protein low in BCAAs for 4 wk with a 2-wk washout in between. At each visit, an oral-glucose-tolerance test (OGTT) was performed. Collected blood samples were used to measure glucose, insulin, and insulin resistance-associated biomarkers. RESULTS:BCAA supplementation tended to decrease the plasma glucose area under the curve (AUC) measured by the OGTT (AUC percentage change from supplementation baseline, BCAA: -3.3% ± 3%; low-BCAA: 10.0% ± 6%; P = 0.08). However, BCAA supplementation did not affect plasma insulin during OGTT challenge (BCAA: -3.9% ± 8%; low-BCAA: 14.8% ± 10%; P = 0.28). The plasma concentrations of nerve growth factor (BCAA: 4.0 ± 1 pg/mL; low-BCAA: 5.7 ± 1 pg/mL; P = 0.01) and monocyte chemoattractant protein-1 (BCAA: -0.4% ± 9%; low-BCAA: 29.0% ± 18%; P = 0.02) were significantly lowered by BCAA supplementation compared to low-BCAA control. Plasma interleukin 1β was significantly elevated by BCAA supplementation (BCAA: 231.4% ± 187%; low-BCAA: 20.6% ± 33%; P = 0.05). BCAA supplementation did not affect the circulating concentrations of the BCAAsleucine (BCAA: 9.0% ± 12%; low-BCAA: 9.2% ± 11%), valine (BCAA: 9.1% ± 11%; low-BCAA: 12.0% ± 13%), or isoleucine (BCAA: 2.5% ± 11%; low-BCAA: 7.3% ± 11%). CONCLUSIONS: Our data suggest that BCAA supplementation did not impair glucose metabolism in obese, prediabetic subjects. Further studies are needed to confirm the results seen in the present study. This study was registered at clinicaltrials.gov as NCT03715010.
Authors: Yan Zheng; Yanping Li; Qibin Qi; Adela Hruby; JoAnn E Manson; Walter C Willett; Brian M Wolpin; Frank B Hu; Lu Qi Journal: Int J Epidemiol Date: 2016-07-13 Impact factor: 7.196
Authors: Luigi Fontana; Nicole E Cummings; Sebastian I Arriola Apelo; Joshua C Neuman; Ildiko Kasza; Brian A Schmidt; Edda Cava; Francesco Spelta; Valeria Tosti; Faizan A Syed; Emma L Baar; Nicola Veronese; Sara E Cottrell; Rachel J Fenske; Beatrice Bertozzi; Harpreet K Brar; Terri Pietka; Arnold D Bullock; Robert S Figenshau; Gerald L Andriole; Matthew J Merrins; Caroline M Alexander; Michelle E Kimple; Dudley W Lamming Journal: Cell Rep Date: 2016-06-23 Impact factor: 9.423
Authors: Giselli Scaini; Lis Mairá Mello-Santos; Camila B Furlanetto; Isabela C Jeremias; Francielle Mina; Patrícia F Schuck; Gustavo C Ferreira; Luiza W Kist; Talita C B Pereira; Maurício R Bogo; Emilio L Streck Journal: Mol Neurobiol Date: 2013-04-05 Impact factor: 5.590
Authors: Kim M Huffman; Svati H Shah; Robert D Stevens; James R Bain; Michael Muehlbauer; Cris A Slentz; Charles J Tanner; Maragatha Kuchibhatla; Joseph A Houmard; Christopher B Newgard; William E Kraus Journal: Diabetes Care Date: 2009-06-05 Impact factor: 19.112
Authors: Cholsoon Jang; Sungwhan F Oh; Shogo Wada; Glenn C Rowe; Laura Liu; Mun Chun Chan; James Rhee; Atsushi Hoshino; Boa Kim; Ayon Ibrahim; Luisa G Baca; Esl Kim; Chandra C Ghosh; Samir M Parikh; Aihua Jiang; Qingwei Chu; Daniel E Forman; Stewart H Lecker; Saikumari Krishnaiah; Joshua D Rabinowitz; Aalim M Weljie; Joseph A Baur; Dennis L Kasper; Zoltan Arany Journal: Nat Med Date: 2016-03-07 Impact factor: 53.440
Authors: Hong Chang Tan; Jean W Hsu; E Shyong Tai; Shaji Chacko; Vieon Wu; Chun Fan Lee; Jean-Paul Kovalik; Farook Jahoor Journal: Front Endocrinol (Lausanne) Date: 2022-06-09 Impact factor: 6.055
Authors: Deirdre K Tobias; Aditi Hazra; Patrick R Lawler; Paulette D Chandler; Daniel I Chasman; Julie E Buring; I-Min Lee; Susan Cheng; JoAnn E Manson; Samia Mora Journal: Sci Rep Date: 2020-10-06 Impact factor: 4.379